SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals, is focused on the research, development and commercialization of treatments for disorders of the central nervous system (CNS), including epilepsy. Both are a part of the global conglomerate SK Group, one of the largest conglomerates in Korea. SK life science, located in Paramus, New Jersey, and SK Biopharmaceuticals, located in Gyeonggi, South Korea, independently developed XCOPRI® (cenobamate tablets) CV from inception through to FDA approval and commercial launch in the U.S. For more information, visit SK life science’s website at www.SKLifeScienceInc.com.